Company / SG&A Expense
Alkermes plc SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$701.5M
FY2025
5-year range
$549.6M / $701.5M
FY2021-FY2025
Trend
+8.7%
vs FY2024
Sector context
#27 of 213
Health Care
What the data says
Alkermes plc's sg&a expense of $702M is higher than 87% of companies in the Health Care sector (FY2025). SG&A Expense has fluctuated over the past 10 years, ranging from $374M in FY2016 to $702M in FY2025.
Based on SEC 10-K filings.
$702M in FY2025 with a 5-year CAGR of +5.4%. Top quartile in the Health Care sector.
Remained stable around $702M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +5.9%
- 5-Year CAGR
- +5.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 213This company $701.5M Sector average $722.3M
▼
-2.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 8.7% year-over-year.
- Ranks #27 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 22.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $701.5M | +8.7% |
| FY2024 | $645.2M | -6.5% |
| FY2023 | $689.8M | +16.8% |
| FY2022 | $590.8M | +7.5% |
| FY2021 | $549.6M | +2.0% |
| FY2020 | $538.8M | -10.1% |
| FY2019 | $599.4M | +13.9% |
| FY2018 | $526.4M | +24.9% |
| FY2017 | $421.6M | +12.7% |
| FY2016 | $374.1M | +221.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026